Last reviewed · How we verify
NCT06178978
Device for Age-related Macular Degeneration (AMD)
trial testing KalEYEdoscope in Age-Related Macular Degeneration in 31 participants. Completed in 25 March 2022.
25 March 2022
Quick facts
| Lead sponsor | University of Michigan |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 31 |
| Start date | 10 March 2022 |
| Primary completion | 25 March 2022 |
| Estimated completion | 25 March 2022 |
| Sites | 1 location across United States |
Drugs / interventions tested
- KalEYEdoscope
Conditions studied
- Age-Related Macular Degeneration — all drugs for Age-Related Macular Degeneration →
Sponsor
University of Michigan
Who can join
18 and older, any sex, with Age-Related Macular Degeneration. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study involves user acceptability and feedback of KalEYEdoscope, a digital, handheld device utilizing shape-discrimination hyperacuity to distinguish the severity of age-related macular degeneration (AMD).
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Novel Handheld Device for Remote Monitoring of Dry Macular Degeneration and Patient Usability Assessment.
Yim AC, Azzouz L, Paulus YM. · · 2025 · PMID 40506926 · DOI 10.3390/diagnostics15111353
Verify or expand the search:
- PubMed search for NCT06178978
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Age-Related Macular Degeneration
Currently open trials in the same condition.
- NCT07440225 — A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-002) · Phase 2, PHASE3 · recruiting
- NCT06619405 — AMD and Validation Rod-Meditated Dark Adaptation With Everyday Task Performance · NA · recruiting
- NCT06970665 — A Study About the Safety of ASP3021 Eye Injections and if They Help People in Japan With Vision Loss From Age-related Ma · Phase 4 · recruiting
- NCT06319872 — The Effects of Disulfiram (Antabuse®) on Visual Acuity in Patients With Retinal Degeneration · Phase 1 · recruiting
- NCT06662162 — Microcurrent Stimulation Therapy for Intermediate to Advanced Nonexudative Age-related Macular Degeneration · NA · recruiting
Other University of Michigan trials
Trials by the same sponsor.
- NCT07536919 — Integrating Care for Hypertension-Diabetes MULTImorbidity in Guatemala Through HEARTS Implementation · NA · not yet recruiting
- NCT05509842 — Function-based Accelerated Stimulation Therapy (FAST-therapy) for Freezing of Gait (FOG) After Parkinson's Disease (PD) · NA · not yet recruiting
- NCT06311188 — Exploring PTSD Symptoms, Barriers and Facilitators to Mindfulness · NA · not yet recruiting
- NCT07471646 — Effects of Ramadan Fasting With Exercise on Cardiometabolic Health · NA · not yet recruiting
- NCT06671925 — A Community Health Worker-Led Program for Chronic Pain and Loneliness in Older Adults · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06178978 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Michigan
- Last refreshed: 21 December 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06178978.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing